Pathologic heterogeneity persists in early active multiple sclerosis lesions
about
Paediatric Multiple Sclerosis: Update on Diagnostic Criteria, Imaging, Histopathology and Treatment ChoicesNovel Insights and Therapeutics in Multiple SclerosisB Cells and Autoantibodies in Multiple SclerosisAdvanced MRI and staging of multiple sclerosis lesionsExploring the overlap between multiple sclerosis, tumefactive demyelination and Baló's concentric sclerosis.The role of immune cells, glia and neurons in white and gray matter pathology in multiple sclerosis.Preferential Recruitment of Neutrophils into the Cerebellum and Brainstem Contributes to the Atypical Experimental Autoimmune Encephalomyelitis Phenotype.Identifying Patient-Specific Epstein-Barr Nuclear Antigen-1 Genetic Variation and Potential Autoreactive Targets Relevant to Multiple Sclerosis Pathogenesis.DNA Subtraction of In Vivo Selected Phage Repertoires for Efficient Peptide Pathology Biomarker Identification in Neuroinflammation Multiple Sclerosis ModelCentral role of Th2/Tc2 lymphocytes in pattern II multiple sclerosis lesionsThe brain antigen-specific B cell response correlates with glatiramer acetate responsiveness in relapsing-remitting multiple sclerosis patientsClinical and pathological insights into the dynamic nature of the white matter multiple sclerosis plaque.Myelinosome formation represents an early stage of oligodendrocyte damage in multiple sclerosis and its animal model.Complement C3 on microglial clusters in multiple sclerosis occur in chronic but not acute disease: Implication for disease pathogenesis.Spring cleaning: time to rethink imaging research lines in MS?Multiple sclerosis: Presence of serum antibodies to lipids and predominance of cholesterol recognition.Further understanding of the immunopathology of multiple sclerosis: impact on future treatments.Astrocytes in multiple sclerosis.Molecular image-directed biopsies: improving clinical biopsy selection in patients with multiple tumorsPattern II and pattern III MS are entities distinct from pattern I MS: evidence from cerebrospinal fluid analysis.Periventricular lesions correlate with cortical thinning in multiple sclerosis.Treatment of the First Acute Relapse Following Therapeutic Plasma Exchange in Formerly Glucocorticosteroid-Unresponsive Multiple Sclerosis Patients-A Multicenter Study to Evaluate Glucocorticosteroid Responsiveness.Multimodal partial volume correction: Application to [11C]PIB PET/MRI myelin imaging in multiple sclerosis.Multi-scale MRI spectrum detects differences in myelin integrity between MS lesion types.Progressive multiple sclerosis patients show substantial lesion activity that correlates with clinical disease severity and sex: a retrospective autopsy cohort analysis.Differences in the Reponses to Apheresis Therapy of Patients With 3 Histopathologically Classified Immunopathological Patterns of Multiple Sclerosis.Defining distinct features of anti-MOG antibody associated central nervous system demyelination.Detailed Characterization of T Cell Receptor Repertoires in Multiple Sclerosis Brain Lesions.Metabolic Dysfunction and Peroxisome Proliferator-Activated Receptors (PPAR) in Multiple Sclerosis.Functional Connectivity in Multiple Sclerosis: Recent Findings and Future Directions
P2860
Q26748229-29052C24-AEBC-49DC-B0C1-3719AC9E7566Q26784619-8240B714-1710-41D3-AACD-665A1DDB7FB3Q26801386-E7683578-44E0-4A29-9E6F-71F20DF2760CQ30825494-E1DC780A-B97F-44EA-B854-A7D880566886Q31066773-8C4FA76A-02A3-4358-9496-726F782E3176Q34468304-5E528C97-6CD0-436E-82E7-0C8A36C0A484Q35861951-6A88158A-95B0-454A-A47C-23803B4FF07CQ35915780-29A337CE-1B5F-4260-AD7D-AC5A510900B2Q35936655-7C6BB2AA-0392-41B0-8021-EB96487FB363Q36072420-71295F46-12C3-46B1-BF6A-BDF2EF094F98Q36099150-6997C87C-2FFB-442D-B99E-CCADD19914DBQ36218017-ED36887C-5533-424E-A580-761B7F882D1EQ37423770-1292303E-DCE8-434E-BFFC-5662E10EA89BQ37561684-5044A3F7-9F81-4196-8549-7AEA5D96CA6FQ38737202-79627F84-443F-4F8A-85F7-B8E0A8650063Q38798705-4FB38778-0629-44CC-9DC5-90821FB10BD9Q38837294-33C1434D-3FCD-4EAA-B427-A7CA87DA70F4Q38840390-191F05B1-0918-4DA0-A712-02ABE8A11F75Q39330511-E4BCF874-2399-4855-BFCA-76E0A569C3EEQ40066335-2BED418E-6D7F-46AF-9A83-209009065374Q40825942-8F68CF8C-53DC-416F-90BD-8E64D82A817CQ41574108-C333A3FC-AC44-4B1C-B468-1A84F0EDB5F6Q47821841-0FEAD443-5FB8-4DCB-85CE-4F8C2BB10DF8Q49015241-BE978E39-FA06-477E-BEDA-BE441BA6B909Q50021192-27C39A5F-028B-43DF-ADB2-B3364265D173Q50194965-D9CE0EC3-ED1E-4C20-A5F6-C9900222DEB0Q52603606-5399A8E0-84BD-4526-83BF-68B6C9148596Q54937236-85643FEE-CB4D-4FB2-BA91-2C7B78B31105Q55561652-70BFEAA2-865E-4027-80D7-47911DDA2000Q58573154-E2ED110D-42BE-428F-8D6B-7F0EB7C06211
P2860
Pathologic heterogeneity persists in early active multiple sclerosis lesions
description
2014 nî lūn-bûn
@nan
2014 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Pathologic heterogeneity persists in early active multiple sclerosis lesions
@ast
Pathologic heterogeneity persists in early active multiple sclerosis lesions
@en
type
label
Pathologic heterogeneity persists in early active multiple sclerosis lesions
@ast
Pathologic heterogeneity persists in early active multiple sclerosis lesions
@en
prefLabel
Pathologic heterogeneity persists in early active multiple sclerosis lesions
@ast
Pathologic heterogeneity persists in early active multiple sclerosis lesions
@en
P2093
P2860
P356
P1433
P1476
Pathologic heterogeneity persists in early active multiple sclerosis lesions
@en
P2093
Bogdan F G Popescu
Claudia F Lucchinetti
Joseph E Parisi
Stephen D Weigand
Wolfgang Brück
P2860
P304
P356
10.1002/ANA.24163
P577
2014-05-13T00:00:00Z